BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-460

  1. 271 Posts.
    lightbulb Created with Sketch. 63
    a small error in the article:

    The company is also completing patient enrolment this quarter of a study using BTX 1503 BTX 1204 to treat atopic dermatitis, with results expected early next year.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.